Phase I trial of antisense oligonucleotide Bcl-2 in patients with follicular lymphoma and solid tumours

Trial Profile

Phase I trial of antisense oligonucleotide Bcl-2 in patients with follicular lymphoma and solid tumours

Planning
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2015

At a glance

  • Drugs Antisense oligonucleotide Bcl-2 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Mar 2015 Bio-Path anticipates filing an IND application with the U.S. FDA in 2015 after completion of preclinical studies. Bio-Path expects that the favourable toxicity profile of the first (BP-100-1-01) drug will allow this study of the second drug to start at a higher dose, thus reducing the number of patients required to complete the safety phase of the study.
    • 16 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top